Gwo Xi Stem Cell Applied Technology , Ltd (6704.TWO) has a profit margin of -49.36%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for 6704.TWO is -49.36% as of June 2026. That compares with -59.85% in the prior-year period — up 17.5% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Gwo Xi Stem Cell Applied Technology , Ltd's historical trend and sector peers before judging valuation or financial health.
Over the past year, 6704.TWO's profit margin moved from -59.85% to -49.36% — a 17.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gwo Xi Stem Cell Applied Technology , Ltd's valuation or profitability profile.
Against Healthcare companies, 6704.TWO currently prints -49.36% for profit margin, while the sector average sits near 17.63%. That is roughly 380.0% below the sector mean. Large gaps often invite a closer look at Gwo Xi Stem Cell Applied Technology , Ltd's growth, margins, and balance sheet.
Profit Margin shows how effectively Gwo Xi Stem Cell Applied Technology , Ltd converts resources into returns. At -49.36%, 6704.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -59.85% in the prior-year period — up 17.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6704.TWO's profit margin (-49.36%), review year-over-year change from -59.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.